MX2023004635A - Los inhibidores de atp mitocondrial que fijan como objetivo la subunidad gamma previenen la metastasis. - Google Patents
Los inhibidores de atp mitocondrial que fijan como objetivo la subunidad gamma previenen la metastasis.Info
- Publication number
- MX2023004635A MX2023004635A MX2023004635A MX2023004635A MX2023004635A MX 2023004635 A MX2023004635 A MX 2023004635A MX 2023004635 A MX2023004635 A MX 2023004635A MX 2023004635 A MX2023004635 A MX 2023004635A MX 2023004635 A MX2023004635 A MX 2023004635A
- Authority
- MX
- Mexico
- Prior art keywords
- atp5f1c
- mitochondrial
- atp
- mitochondrial atp
- metastasis
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title abstract 3
- 230000009401 metastasis Effects 0.000 title abstract 3
- 230000002438 mitochondrial effect Effects 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102100032763 ATP synthase subunit gamma, mitochondrial Human genes 0.000 abstract 4
- 101000730170 Homo sapiens ATP synthase subunit gamma, mitochondrial Proteins 0.000 abstract 4
- 230000002407 ATP formation Effects 0.000 abstract 2
- 102000013379 Mitochondrial Proton-Translocating ATPases Human genes 0.000 abstract 2
- 108010026155 Mitochondrial Proton-Translocating ATPases Proteins 0.000 abstract 2
- QUIJNHUBAXPXFS-XLJNKUFUSA-N bedaquiline Chemical compound C1([C@H](C2=CC3=CC(Br)=CC=C3N=C2OC)[C@@](O)(CCN(C)C)C=2C3=CC=CC=C3C=CC=2)=CC=CC=C1 QUIJNHUBAXPXFS-XLJNKUFUSA-N 0.000 abstract 2
- 206010061309 Neoplasm progression Diseases 0.000 abstract 1
- 238000011319 anticancer therapy Methods 0.000 abstract 1
- 229960000508 bedaquiline Drugs 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000005750 disease progression Effects 0.000 abstract 1
- 238000009509 drug development Methods 0.000 abstract 1
- 125000005313 fatty acid group Chemical group 0.000 abstract 1
- 238000003197 gene knockdown Methods 0.000 abstract 1
- 230000004547 gene signature Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002269 spontaneous effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000005751 tumor progression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La alta producción de ATP por la ATP-sintasa mitocondrial es un nuevo objetivo terapéutico para la terapia anticancerosa, especialmente para prevenir el progreso de tumores. Se describe una firma de genes relacionados con mitocondrias para la metástasis, la cual presenta la subunidad gamma de la ATP-sintasa mitocondrial (ATP5F1C). La supresión de la expresión de ATP5F1C reduce significativamente la producción de ATP, el crecimiento independiente del anclaje 3D y la migración de células. La administración de la Bedaquilina, o un derivado de Bedaquilina con una porción de ácido graso, regula por decremento la expresión de ATP5F1C in vitro y previene la metástasis espontánea in vivo. La ATP5F1C mitocondrial es un nuevo biomarcador prometedor y un objetivo molecular para el futuro desarrollo de fármacos, para la prevención del progreso de enfermedades metastásicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104160P | 2020-10-22 | 2020-10-22 | |
| PCT/IB2021/059772 WO2022084947A1 (en) | 2020-10-22 | 2021-10-22 | Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004635A true MX2023004635A (es) | 2023-05-12 |
Family
ID=81290213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004635A MX2023004635A (es) | 2020-10-22 | 2021-10-22 | Los inhibidores de atp mitocondrial que fijan como objetivo la subunidad gamma previenen la metastasis. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240010622A1 (es) |
| EP (1) | EP4232432A1 (es) |
| JP (1) | JP2023547108A (es) |
| KR (1) | KR20230092999A (es) |
| CN (1) | CN116437922A (es) |
| CA (1) | CA3198350A1 (es) |
| IL (1) | IL302095A (es) |
| MX (1) | MX2023004635A (es) |
| WO (1) | WO2022084947A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
| RU2019142102A (ru) * | 2017-05-19 | 2021-06-21 | Лунелла Байотек, Инк. | Антимитосцины: направленные ингибиторы митохондриального биогенеза для эрадикации злокачественных стволовых клеток |
| CA3180522A1 (en) * | 2020-04-24 | 2021-10-28 | Lunella Biotech, Inc. | Therapeutic methods for preventing tumor metastasis and tumor recurrence |
-
2021
- 2021-10-22 IL IL302095A patent/IL302095A/en unknown
- 2021-10-22 WO PCT/IB2021/059772 patent/WO2022084947A1/en active Application Filing
- 2021-10-22 KR KR1020237017073A patent/KR20230092999A/ko unknown
- 2021-10-22 MX MX2023004635A patent/MX2023004635A/es unknown
- 2021-10-22 CA CA3198350A patent/CA3198350A1/en active Pending
- 2021-10-22 US US18/033,266 patent/US20240010622A1/en active Pending
- 2021-10-22 JP JP2023524398A patent/JP2023547108A/ja active Pending
- 2021-10-22 EP EP21882299.7A patent/EP4232432A1/en active Pending
- 2021-10-22 CN CN202180074119.1A patent/CN116437922A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232432A1 (en) | 2023-08-30 |
| WO2022084947A1 (en) | 2022-04-28 |
| JP2023547108A (ja) | 2023-11-09 |
| US20240010622A1 (en) | 2024-01-11 |
| CN116437922A (zh) | 2023-07-14 |
| IL302095A (en) | 2023-06-01 |
| KR20230092999A (ko) | 2023-06-26 |
| CA3198350A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Icard et al. | How the Warburg effect supports aggressiveness and drug resistance of cancer cells? | |
| Zhu et al. | Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics | |
| PH12020550685A1 (en) | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells | |
| US9517245B2 (en) | Sorafenib-microRNA combination therapy for liver cancer | |
| JP2020530467A5 (es) | ||
| Liu et al. | Eupafolin suppresses prostate cancer by targeting phosphatidylinositol 3‐kinase‐mediated Akt signaling | |
| Zhang et al. | Research progress on therapeutic targeting of quiescent cancer cells | |
| Carvalho et al. | The peculiarities of cancer cell metabolism: A route to metastasization and a target for therapy | |
| Kil et al. | Anticancer effect of silibinin on the xenograft model using MDA-MB-468 breast cancer cells | |
| MX2023004635A (es) | Los inhibidores de atp mitocondrial que fijan como objetivo la subunidad gamma previenen la metastasis. | |
| CN104610435B (zh) | 一种能靶向抑制erk信号通路的抗肿瘤多肽及其应用 | |
| IL259512B2 (en) | Combination for effective treatment of metastatic cancer in patients | |
| Fu et al. | Stromal disruption facilitating invasion of a ‘nano-arsenal’into the solid tumor | |
| KR20210139237A (ko) | 변형된 마이크로rna 및 암 치료에 있어서의 이의 용도 | |
| Kunnath et al. | Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumour in an immunocompetent mouse | |
| Yutkin et al. | Apaziquone as an intravesical therapeutic agent for urothelial non-muscle-invasive bladder cancer | |
| Barnhart et al. | Taking aim at translation for tumor therapy | |
| Stover et al. | Sensitizing cancer cells: is it really all about U? | |
| CN115364109B (zh) | 一种用于肺癌治疗的药物制剂 | |
| CN114010624B (zh) | 双硫仑和甲氨蝶呤在制备抗肝癌药物中的应用 | |
| Moscat et al. | Nutrient stress revamps cancer cell metabolism | |
| CN113663081A (zh) | 千层纸素和pd-1/pd-l1抑制剂在制备肝癌治疗药物中的应用 | |
| WO2021101258A3 (ko) | 압타머 기반 표적화 복합 항암제 | |
| Guilford et al. | Antiparasitic and antifungal medications for targeting cancer cells literature review and case studies | |
| Abreu et al. | Targeting the Warburg effect for cancer therapy: A long and winding road |